Compare iShares MSCI South Africa ETF (EZA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MSCI South Africa ETF trades at $62.78, while Vertex Pharmaceuticals Incorporated trades at $484.87 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| EZA | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $529.59 |
52-Week Low | $53.05 | $366.54 |
Market Cap | — | $121.09B |
Enterprise Value | — | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA is trading at $62.83, down 0.98% on the day, with a bearish technical outlook indicated by moving averages and overall momentum. The stock shows neutral oscillator readings but faces selling pressure according to ADX indicators. Recent corporate actions include a $1.43 dividend scheduled for June 2026, providing some income appeal despite current technical weakness.
The stock faces headwinds from bearish technical signals while lacking current fundamental data for comprehensive analysis. Investment opportunity exists through the upcoming dividend, but requires monitoring of earnings reports and financial metrics once available. Key risks include market volatility and the need for updated financial disclosures to assess true valuation.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
